Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock
NASDAQ · MLYS
Key stats
- Market cap
- $1.43B
- Price / Earnings ratio
- -3.7x
- EPS (TTM)
- -$4.31
- Volume
- Loading
- 52-week high
- $47.65
- 52-week low
- $14.91
Source: third-party data provider, as of November 13, 2026
Compare with MLYS
Recent news

MarketBeat
Mineralys Therapeutics Q2 Earnings Call Highlights
MLYSAugust 11, 2026
MarketBeat
Mineralys Therapeutics Q2 Earnings Call Highlights
MLYS

Reuters
Mineralys' pill cuts blood pressure in kidney disease patients
MLYSMay 30, 2026
Reuters
Mineralys' pill cuts blood pressure in kidney disease patients
MLYS

The Motley Fool
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
MLYSApril 7, 2026
The Motley Fool
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
MLYS

Zacks Investment Research
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYSMarch 11, 2026
Zacks Investment Research
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYS
Technical indicators
- RSI 14
- 34.61
- MACD 12/26/9
- -2.13
- EMA 9 of MACD
- -1.97
- MACD histogram
- -0.16
- SMA 50
- $23.19
- Price below SMA 50
- EMA 50
- $21.57
- Price below EMA 50
- SMA 200
- $26.32
- Price below SMA 200
- EMA 200
- $27.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold1
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
794M524M262M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-154.7M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Mineralys Therapeutics Q2 Earnings Call Highlights
MLYSAugust 11, 2026
MarketBeat
Mineralys Therapeutics Q2 Earnings Call Highlights
MLYS

Reuters
Mineralys' pill cuts blood pressure in kidney disease patients
MLYSMay 30, 2026
Reuters
Mineralys' pill cuts blood pressure in kidney disease patients
MLYS

The Motley Fool
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
MLYSApril 7, 2026
The Motley Fool
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
MLYS

Zacks Investment Research
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYSMarch 11, 2026
Zacks Investment Research
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYS

Zacks Investment Research
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
MLYSDecember 26, 2025
Zacks Investment Research
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
MLYS

Zacks Investment Research
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
MLYSDecember 24, 2025
Zacks Investment Research
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
MLYS

The Motley Fool
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
MLYSDecember 23, 2025
The Motley Fool
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
MLYS

The Motley Fool
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
MLYSSeptember 16, 2025
The Motley Fool
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
MLYS

Seeking Alpha
What To Buy After You Sell The Russell 2000
MLYSApril 3, 2024
Seeking Alpha
What To Buy After You Sell The Russell 2000
MLYS

Seeking Alpha
Strong Small-Cap Insider Buys: Q1 2023
MLYSApril 26, 2023
Seeking Alpha
Strong Small-Cap Insider Buys: Q1 2023
MLYS
About Mineralys Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees76
CEODr. Jon Congleton
IPO DateFeb 8, 2023
HeadquartersRadnor, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jon Congleton | President, CEO & Director | 1963 |
| Mr. Adam Scott Levy | CFO & Secretary | 1978 |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Director | 1977 |
| Mr. Jeffrey A. Munsie J.D. | Chief Legal Officer | 1977 |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC | — |
| Ms. Danielle Mahoney | Senior Vice President of Quality Assurance | — |
| Ms. Jessica Ibbitson | Executive Vice President of Operations | — |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 1972 |
| Mr. Michael Tortorici Ph.D., Pharm.D. | Senior Vice President of Translational Medicine | — |
| Dr. James J. Ferguson III, FACC, M.D. | Chief Medical Officer | 1954 |
Fundamentals
Valuation
Price-to-book value2.73
Profitability
Return on Equity-58.00%
Return on Assets-54.00%
EBITDA$-349.54M
Trading
Average volume1,904,975
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.61
- MACD 12/26/9
- -2.13
- EMA 9 of MACD
- -1.97
- MACD histogram
- -0.16
- SMA 50
- $23.19
- Price below SMA 50
- EMA 50
- $21.57
- Price below EMA 50
- SMA 200
- $26.32
- Price below SMA 200
- EMA 200
- $27.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Hold
50% Buy
50% Hold
0% Sell
Analyst price target
- Low
- $29.00
- Average
- $42.50
- High
- $56.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -3.6 | -11.8 | -12.4 | +6.4 | +17.8 | -11.5 | -7.3 | -26.4 | -15.3 | -14.1 | +19.4 | |
| 2024 | +25.7 | +21.1 | -15.8 | -6.0 | -0.2 | -10.6 | +1.8 | +3.0 | +1.3 | +9.0 | -5.1 | -8.7 |
| 2025 | -15.9 | -8.0 | +77.6 | +2.7 | +4.1 | -13.8 | +3.3 | +13.2 | +31.4 | +2.6 | +10.1 | -10.9 |
| 2026 | -13.5 | -5.2 | -7.6 | +0.9 | +7.7 | -13.3 | -5.1 | -0.4 | -1.7 | -23.4 | +3.9 |
Compare stocks
Market cap
$1.43B
-
-
-
Price / Earnings ratio
-3.70
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,904,975
-
-
-
Earnings per share
$-4.31
-
-
-



